Neoadjuvant ipilimumab added to nivolumab improves outcomes in resectable advanced melanoma

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

No benefit for adjuvant durvalumab in completely resected NSCLC

PFS increase but no OS increase for niraparib in advanced ovarian cancer

ESMO 2024: Highlights and analysis

Watchful waiting vs intravesical BCG in high grade pT1 bladder cancer

Durvalumab and oleclumab boost for SBRT plus chemo in ER+/HER2- breast cancer

Faecal microbiota transplantation increases activity of immunotherapy in mRCC

Zanidatamab investigated for HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma

Novel antibody drug conjugate TORL-1-23 shows preliminary antitumour activity in heavily-pretreated ovarian, endometrial, and testicular cancers

Total neoadjuvant treatment without surgery for locally advanced rectal cancer

Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy